LMB-9 immunotoxin

BIOLOGICAL3 trials

Sponsors

University of Maryland, Baltimore, University Hospital Freiburg, National Cancer Institute (NCI)

Conditions

Bladder CancerBreast CancerColorectal CancerEsophageal CancerGastric CancerLung CancerOvarian CancerPancreatic Cancer

Phase 1

LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer

University Hospital FreiburgColorectal Cancer, Esophageal Cancer, Gastric Cancer +1

Start: 2001-04-30Target: 50Updated: 2013-12-19

LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer

CompletedNCT00005858

University of Maryland, BaltimoreBladder Cancer, Breast Cancer, Colorectal Cancer +3

Start: 2000-04-30End: 2003-12-31Updated: 2019-11-04

LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors

CompletedNCT00019435

National Cancer Institute (NCI)Bladder Cancer, Breast Cancer, Colorectal Cancer +4

Start: 1998-05-31Updated: 2015-04-29

Related Papers

Immunotoxin Therapy for Lung Cancer

Chinese Medical Journal2017-02-201 citations